Repro Stock Analysis

KRMD -  USA Stock  

USD 2.75  0.01  0.36%

The latest surge in Repro Med short term price appreciation may raise some interest from shareholders. The stock closed today at a share price of 2.75 on very low momentum in trading volume. The company management teams have successfully maneuvered the company at convenient times to take advantage of all market conditions in December. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.0. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Repro Med partners.
Please see Stocks Correlation.

Repro Stock Analysis 

The Repro Med stock analysis report makes it easy to digest most publicly released information about Repro Med and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Repro Stock analysis module also helps to analyze the Repro Med price relationship with some important fundamental indicators such as market cap and management efficiency.

Repro Stock Analysis Notes

About 58.0% of the company shares are owned by institutional investors. The book value of Repro Med was now reported as 0.83. The company recorded a loss per share of 0.1. Repro Med Sys had not issued any dividends in recent years. Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York. Repro Med operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. To find out more about Repro Med Sys contact the company at 845 469 2042 or learn more at

Repro Med Quarterly Cost of Revenue

2.54 MillionShare

Repro Med Sys Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Repro Med's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Repro Med Sys or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Repro Med Sys has very high historical volatility over the last 90 days
Repro Med Sys is unlikely to experience financial distress in the next 2 years
Repro Med Sys was previously known as Repro Med Systems and was traded on NASDAQ Exchange under the symbol REPR.
The company reported the previous year's revenue of 21.06 M. Net Loss for the year was (4.33 M) with profit before overhead, payroll, taxes, and interest of 15.01 M.
Repro Med Sys currently holds about 26.23 M in cash with (5.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59.
Repro Med Sys has a frail financial position based on the latest SEC disclosures
Roughly 58.0% of the company shares are owned by institutional investors
Latest headline from Sema4 secures a deal to acquire GeneDx, capturing 200M in private investment - MedCity News

Repro Med Sys Upcoming and Recent Events

Earnings reports are used by Repro Med to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Repro Med previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report22nd of March 2022
Next Earnings Report11th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End22nd of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Repro Largest EPS Surprises

Earnings surprises can significantly impact Repro Med's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Repro Med SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Repro Med prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Repro Med investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Repro Med Sys specific information freely available to individual and institutional investors to make a timely investment decision.
10th of December 2021
Regulation FD Disclosure
7th of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure
10th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
11th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
19th of May 2021
Submission of Matters to a Vote of Security Holders
12th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
6th of April 2021
Unclassified Corporate Event

Repro Med Thematic Classifications

In addition to having Repro Med stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Medical Equipment IdeaMedical Equipment
USA Equities from Medical Equipment industry as classified by Fama & French

Repro Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Repro Med is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Repro Med Sys backward and forwards among themselves. Repro Med's institutional investor refers to the entity that pools money to purchase Repro Med's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Horton Capital Management LlcCommon Shares10.8 M30.7 M
First Light Asset Management LlcCommon Shares5.4 M15.4 M
Archon Capital Management LlcCommon Shares2.4 MM
Vanguard Group IncCommon Shares1.3 M3.8 M
Albion Financial GroupCommon Shares1000 K2.9 M
Altium Capital Management LpCommon Shares954.1 K2.7 M
Royal Bank Of CanadaCommon Shares507.2 K1.4 M
Note, although Repro Med's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Repro Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 122.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Repro Med's market, we take the total number of its shares issued and multiply it by Repro Med's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Repro Profitablity

Repro Med's profitability indicators refer to fundamental financial ratios that showcase Repro Med's ability to generate income relative to its revenue or operating costs. If, let's say, Repro Med is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Repro Med's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Repro Med's profitability requires more research than a typical breakdown of Repro Med's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (20.56) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (20.94) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.21.
Last ReportedProjected for 2022
Return on Average Assets(0.0288) (0.0296) 
Return on Average Equity(0.0342) (0.0351) 
Return on Invested Capital(0.17) (0.17) 
Return on Sales(0.0441) (0.0453) 

Management Efficiency

The entity has return on total asset (ROA) of (6.35) % which means that it has lost $6.35 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (11.28) %, meaning that it created substantial loss on money invested by shareholders. Repro Med management efficiency ratios could be used to measure how well repro med sys manages its routine affairs as well as how well it operates its assets and liabilities. As of January 23, 2022, Return on Average Assets is expected to decline to -0.03. In addition to that, Return on Average Equity is expected to decline to -0.04. Repro Med Current Assets are projected to increase significantly based on the last few years of reporting. The past year's Current Assets were at 43.15 Million. The current year Goodwill and Intangible Assets is expected to grow to about 1 M, whereas Tax Assets are forecasted to decline to about 128 K.
Last ReportedProjected for 2022
Book Value per Share 0.99  1.07 
Enterprise Value over EBIT(224.25) (230.15) 
Enterprise Value over EBITDA(269.63) (276.72) 
Price to Book Value 8.41  7.72 
Tangible Assets Book Value per Share 1.07  1.16 
Enterprise Value267.2 M288.3 M
Tangible Asset Value44.9 M48.5 M

Technical Drivers

As of the 23rd of January, Repro Med holds the Risk Adjusted Performance of 0.0281, coefficient of variation of 4248.94, and Semi Deviation of 4.6. Repro Med Sys technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We have collected data for nineteen technical drivers for Repro Med Sys, which can be compared to its competitors. Please check Repro Med Sys treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Repro Med Sys is priced some-what accurately, providing market reflects its current price of 2.75 per share. Please also confirm Repro Med Sys total risk alpha, which is currently at 0.5476 to check out the company can sustain itself at a future point.

Repro Med Sys Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Repro Med Sys more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Repro Med Sys Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repro Med insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repro Med's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Repro Med insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Repro Med Technical and Predictive Indicators

Repro Med Forecast Models

Repro Med time-series forecasting models is one of many Repro Med's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Repro Med's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Repro Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Repro Med stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Repro shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Repro Med. By using and applying Repro Stock analysis, traders can create a robust methodology for identifying Repro entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(0.0288) (0.0296) 
Gross Margin 0.56  0.56 
Profit Margin(0.045) (0.0462) 
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York. Repro Med operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.

Current Repro Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Repro analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Repro analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Repro Med Sys current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Repro analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Repro stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Repro Med Sys, talking to its executives and customers, or listening to Repro conference calls.
Repro Analyst Advice Details

Repro Stock Analysis Indicators

Repro Med Sys stock analysis indicators help investors evaluate how Repro Med stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Repro Med shares will generate the highest return on investment. By understating and applying Repro Med stock analysis, traders can identify Repro Med position entry and exit signals to maximize returns.
Quick Ratio6.44
Fifty Two Week Low2.3000
Revenue Growth-0.70%
Shares Short Prior Month824.3k
Average Daily Volume Last 10 Day167.9k
Average Daily Volume In Three Month183.73k
Shares Percent Shares Out1.30%
Gross Margins58.44%
Short Percent Of Float2.50%
Forward Price Earnings-17.19
Float Shares25.26M
Fifty Two Week High5.2300
Enterprise Value To Ebitda-27.26
Fifty Day Average3.2138
Two Hundred Day Average3.4030
Enterprise Value To Revenue5.10
Please see Stocks Correlation. Note that the Repro Med Sys information on this page should be used as a complementary analysis to other Repro Med's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Repro Stock analysis

When running Repro Med Sys price analysis, check to measure Repro Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repro Med is operating at the current time. Most of Repro Med's value examination focuses on studying past and present price action to predict the probability of Repro Med's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Repro Med's price. Additionally, you may evaluate how the addition of Repro Med to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Is Repro Med's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Repro Med Sys is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine Repro Med value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.